GlassScriptPhysician profile
Raquel Watkins
NPI 1205036084
$7,865.35
in general payments reported to CMS, 2019-2025
29 companies · $3,672 in 2025
The $3,672 reported for 2025 was more than what 80% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $842 · 2020: $202 · 2021: $167 · 2022: $716 · 2023: $1,017 · 2024: $1,249 · 2025: $3,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,373 · Consulting Fee: $1,467 · Education: $98.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,372.68 |
| Consulting Fee | $1,466.64 |
| Education | $98.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,240.21 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $859.15 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $802.14 | 2019-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $655.81 | 2022-2025 | Orladeyo |
| Glaxosmithkline, LLC. | $515.79 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Csl Behring | $334.73 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Pfizer INC. | $317.39 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $314.77 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Novartis Pharmaceuticals Corporation | $246.64 | 2019-2025 | |
| Pharming Healthcare, INC. | $179.48 | 2019-2025 | Ruconest |
| Abbvie INC. | $167.37 | 2022-2024 | Rinvoq |
| Optinose US, INC. | $156.88 | 2019-2025 | |
| Amgen INC. | $150.99 | 2022-2025 | Tezspire |
| Grifols USA, LLC | $150.98 | 2022-2025 | Xembify, Gamunex-C |
| Incyte Corporation | $133.55 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $105.31 | 2019-2025 | Xolair |
| Alk-Abello, INC | $94.28 | 2019-2025 | Grastek, Odactra, Ragwitek |
| Hikma Pharmaceuticals USA | $87.33 | 2024-2025 | Ryaltris, Kloxxado |
| Kaleo, INC. | $61.92 | 2019-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.25 | 2019-2023 | Spiriva Respimat |
| Leo Pharma INC. | $46.14 | 2023-2025 | Anzupgo, Adbry |
| Circassia INC. | $30.33 | 2019 | |
| Blueprint Medicines Corporation | $29.94 | 2023 | Ayvakit |
| Shire North American Group INC | $28.74 | 2019 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Lilly USA, LLC | $24.22 | 2025 | Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $23.50 | 2025 | Neffy |
| Adma Biomanufacturing LLC | $20.64 | 2025 | |
| Paratek Pharmaceuticals, INC. | $13.63 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raquel Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.